🚀 VC round data is live in beta, check it out!
- Public Comps
- APT Medical
APT Medical Valuation Multiples
Discover revenue and EBITDA valuation multiples for APT Medical and similar public comparables like Snibe, Ypsomed, Andon Health, Imeik Technology Development and more.
APT Medical Overview
About APT Medical
APT Medical Inc is engaged in the research and development, production and sales of electrophysiological and vascular interventional medical devices for cardiovascular and cerebrovascular diseases. Its products are sold in Europe, Eastern Europe, Southeast Asia and other countries and other regions.
Founded
2002
HQ

Employees
N/A
Website
Financials (LTM)
EV
$5B
APT Medical Financials
APT Medical reported last 12-month revenue of $406M and EBITDA of $161M.
In the same LTM period, APT Medical generated $296M in gross profit, $161M in EBITDA, and $129M in net income.
Revenue (LTM)
APT Medical P&L
In the most recent fiscal year, APT Medical reported revenue of $379M and EBITDA of $154M.
APT Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $406M | XXX | $379M | XXX | XXX | XXX |
| Gross Profit | $296M | XXX | $276M | XXX | XXX | XXX |
| Gross Margin | 73% | XXX | 73% | XXX | XXX | XXX |
| EBITDA | $161M | XXX | $154M | XXX | XXX | XXX |
| EBITDA Margin | 40% | XXX | 41% | XXX | XXX | XXX |
| EBIT Margin | 36% | XXX | 37% | XXX | XXX | XXX |
| Net Profit | $129M | XXX | $120M | XXX | XXX | XXX |
| Net Margin | 32% | XXX | 32% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
APT Medical Stock Performance
APT Medical has current market cap of $5B, and enterprise value of $5B.
Market Cap Evolution
APT Medical's stock price is $37.53.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5B | $5B | 0.0% | XXX | XXX | XXX | $0.85 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAPT Medical Valuation Multiples
APT Medical trades at 12.5x EV/Revenue multiple, and 31.4x EV/EBITDA.
EV / Revenue (LTM)
APT Medical Financial Valuation Multiples
As of April 20, 2026, APT Medical has market cap of $5B and EV of $5B.
Equity research analysts estimate APT Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
APT Medical has a P/E ratio of 41.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV/Revenue | 12.5x | XXX | 13.4x | XXX | XXX | XXX |
| EV/EBITDA | 31.4x | XXX | 33.0x | XXX | XXX | XXX |
| EV/EBIT | 34.7x | XXX | 36.6x | XXX | XXX | XXX |
| EV/Gross Profit | 17.1x | XXX | 18.4x | XXX | XXX | XXX |
| P/E | 41.1x | XXX | 44.0x | XXX | XXX | XXX |
| EV/FCF | 53.8x | XXX | 50.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified APT Medical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


APT Medical Margins & Growth Rates
APT Medical's revenue in the last 12 month grew by 27%.
APT Medical's rule of 40 is 66% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
APT Medical's rule of X is 106% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
APT Medical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 27% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Margin | 40% | XXX | 41% | XXX | XXX | XXX |
| EBITDA Growth | 27% | XXX | 24% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 66% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 106% | XXX | XXX | XXX |
| S&M Expenses to Revenue | 18% | XXX | 18% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | 5% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 14% | XXX | 14% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 36% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
APT Medical Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| APT Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Snibe | XXX | XXX | XXX | XXX | XXX | XXX |
| Ypsomed | XXX | XXX | XXX | XXX | XXX | XXX |
| Andon Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Imeik Technology Development | XXX | XXX | XXX | XXX | XXX | XXX |
| Horiba | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
APT Medical M&A Activity
APT Medical acquired XXX companies to date.
Last acquisition by APT Medical was on XXXXXXXX, XXXXX. APT Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by APT Medical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAPT Medical Investment Activity
APT Medical invested in XXX companies to date.
APT Medical made its latest investment on XXXXXXXX, XXXXX. APT Medical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by APT Medical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout APT Medical
| When was APT Medical founded? | APT Medical was founded in 2002. |
| Where is APT Medical headquartered? | APT Medical is headquartered in China. |
| Is APT Medical publicly listed? | Yes, APT Medical is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of APT Medical? | APT Medical trades under 688617 ticker. |
| When did APT Medical go public? | APT Medical went public in 2021. |
| Who are competitors of APT Medical? | APT Medical main competitors are Snibe, Ypsomed, Andon Health, Imeik Technology Development. |
| What is the current market cap of APT Medical? | APT Medical's current market cap is $5B. |
| What is the current revenue of APT Medical? | APT Medical's last 12 months revenue is $406M. |
| What is the current revenue growth of APT Medical? | APT Medical revenue growth (NTM/LTM) is 27%. |
| What is the current EV/Revenue multiple of APT Medical? | Current revenue multiple of APT Medical is 12.5x. |
| Is APT Medical profitable? | Yes, APT Medical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of APT Medical? | APT Medical's last 12 months EBITDA is $161M. |
| What is APT Medical's EBITDA margin? | APT Medical's last 12 months EBITDA margin is 40%. |
| What is the current EV/EBITDA multiple of APT Medical? | Current EBITDA multiple of APT Medical is 31.4x. |
| What is the current FCF of APT Medical? | APT Medical's last 12 months FCF is $94M. |
| What is APT Medical's FCF margin? | APT Medical's last 12 months FCF margin is 23%. |
| What is the current EV/FCF multiple of APT Medical? | Current FCF multiple of APT Medical is 53.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.